Inhaled treatment for bronchiectasis flare-ups
Part of Lungs & breathing clinical trials.
This study tests a new inhaled medicine (called H057) for people having a sudden worsening of bronchiectasis symptoms. The goal is to see if it helps reduce the severity and duration of the flare-up and is safe to use.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must be having a flare-up of your bronchiectasis symptoms that started more than 2 days ago but not more than 7 days ago.
- You need to be able to use a nebulizer (a machine that turns medicine into a mist) on your own.
- You must not have certain other lung conditions, like cystic fibrosis or active tuberculosis.
- You must not have serious liver, kidney, or blood-borne infections (like hepatitis B or C, HIV, or syphilis).
- You must not be pregnant, nursing, or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, HSK31858, for people with non-cystic fibrosis bronchiectasis (a lung condition causing chronic cough and infections). It aims to see if the drug reduces lung flare-ups and improves symptoms.
This trial tests an inhaled medication for adults with bronchiectasis, a lung condition that causes chronic cough and mucus. The goal is to see if the drug is safe and helpful in reducing symptoms and infections.
This study tests how safe an experimental inhaled medicine (HSK31858) is for people with non-cystic fibrosis bronchiectasis, a lung condition where airways are damaged and collect mucus. You can only join if you already completed a previous HSK31858 study.
This trial tests an inhaled medication for people with bronchiectasis, a lung condition causing chronic cough and mucus. It first checks safety in healthy volunteers, then studies how the drug works in people with bronchiectasis.
This trial tests if a new drug, GSK3862995B, is safe and effective for adults with bronchiectasis. It might help reduce lung infections and improve symptoms.
This trial tests an inhaled medication called CSL787 to see if it can help people with non-cystic fibrosis bronchiectasis (a lung condition that causes frequent infections and breathing problems). The study looks at different doses and checks how well the drug works and if it is safe.
Hear when a new Acute Exacerbations of Bronchiectasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.